Commercial products and programs in obesity management
Edmonton; Obesity Canada; June 11, 2020. 8 p.
Non-conventional
em En
| BIGG
| ID: biblio-1509776
Biblioteca responsável:
BR926.1
ABSTRACT
The commercial weight loss industry is enormous. Clinicians should familiarize themselves with the commercial obesity management offerings in their vicinity. Criteria have been published to evaluate whether a commercial program is safe and potentially successful (i.e., offering a combination of nutrition, physical activity and behaviour change support; with realistic weight loss goals of 0.51.0 kg per week, a long-term weight maintenance approach; a good safety profile and reasonable costs). None of the weight loss products from the commercial industry that were studied in randomized control trials of more than 12 weeks duration were shown to produce clinically meaningful weight loss. Some commercial programs that combine nutrition, physical activity and support (Jenny Craig®, Nutrisystem®, Optifast®, WW® (formerly Weight Watchers) can be used to induce modest weight loss. Some programs have also shown improvement in glycemic control in patients with obesity and diabetes but no effect on lipids or blood pressure have been demonstrated.
Texto completo:
1
Coleções:
05-specialized
Base de dados:
BIGG
Assunto principal:
Fármacos Antiobesidade
/
Indústria Farmacêutica
/
Manejo da Obesidade
/
Obesidade
Tipo de estudo:
Clinical_trials
/
Guideline
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Non-conventional
País de publicação:
Canadá